SOCRATES REDUCED

• Research type

  Research Study

• Full title

  Study title: A randomized parallel-group, placebo-controlled, double-blind, multicenter dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four dose regimens of the oral sGC stimulator BAY 1021189 over 12 weeks in patients with worsening heart failure and reduced ejection fraction (HFrEF) - SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with REDUCED EF

• IRAS ID

  152242

• Contact name

  Diana Gorog

• Contact email

  d.gorog@nhs.net

• Eudract number

  2013-002287-11

• Clinicaltrials.gov Identifier

  NCT01951625

• Research summary

  Objective of the study is the find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase IIIt that can be given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).

• REC name

  London - Fulham Research Ethics Committee

• REC reference

  14/LO/0675

• Date of REC Opinion

  4 Jun 2014

• REC opinion

  Further Information Favourable Opinion